A new approach helps examine the proportion of cancerous and healthy stem cells in patients with chronic myeloid leukemia and how this influences treatment outcomes.

Many of us remember from high school biology class that mitochondria are the cell's "power plants." These small ...

Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI), today reported financial results for the third quarter ended September 30 ...

Neuroblastoma (NB), the most prevalent extracranial solid tumor in children, poses a significant therapeutic challenge due to ...

Oculis has multiple late-stage programs and catalysts. Click here to find out why I think OCS stock looks attractive.

Neuroblastoma (NB), the most prevalent extracranial solid tumor in children, poses a significant therapeutic challenge due to ...

The committee was not convinced that the benefit of Zynquista outweighed the risk in adults with type 1 diabetes and chronic ...

Lexicon Pharmaceuticals shares tumbled in premarket trading Friday after a Food and Drug Administration advisory committee's negative vote on the biopharmaceutical company's Zynquista as an adjunct to ...

Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023- -NDA Submission for Brensocatib in Bronchiectasis Remains on Track for the Fourth ...

The risk for an incident diagnosis of type 2 diabetes is increased in the 6 months following SARS-CoV-2 infection.

"The publication of the Chinese subpopulation data from the NEFECON® global Phase 3 NefIgArd clinical trial in the 'Kidney 360' magazine further supports the clinical evidence of NEFECON® in the ...